Skip to content

UK Validation of the Automated "AcceXible" Speech Analysis Software

Assessing the Diagnostic Accuracy of a Three One-minute Tests of Verbal Fluency, Using Artificial Intelligence, in Detecting Mild Cognitive Impairment and Early Dementia.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05534958
Enrollment
221
Registered
2022-09-10
Start date
2022-11-18
Completion date
2024-12-31
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment and Dementia

Brief summary

Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear. The sooner the patient is diagnosed, the sooner the patient will be in a position to prevent further deterioration. A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. The present study has the objective of validating a digital method for detection and follow-up of patients with mild cognitive impairment (MCI) or dementia in a memory clinic setting.

Interventions

DEVICEAccexible

Speech Analysis

Sponsors

Accexible
Lead SponsorINDUSTRY
Cornwall Partnership NHS Foundation Trust
CollaboratorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
55 Years to 90 Years

Inclusion criteria

for patients: * Adult patients 55+ years of age with suspected MCI or diagnosis of dementia referred into secondary care memory clinic by their General Practitioner. * Have English as first language (able to speak and understand verbal messages). * Patients must have agreed to participate in the study and have voluntarily signed the informed consent. Inclusion Criteria for healthy volunteers: * Healthy older adults (55+ years of age), without a diagnosis neurological, or psychiatric disorders or any clinical evidence of cognitive decline. * Have English as first language (able to speak and understand verbal messages). * Controls must have agreed to participate in the study and have voluntarily signed the informed consent.

Exclusion criteria

for patients: * To have received a diagnosis of a significant psychiatric disorder or other cognitive impairment not due to neurodegeneration. * To have significant vision problems that would affect the ability to perceive visual stimuli. * To have significant hearing problems that would affect the ability to understand verbal cues. * To be unable to give informed consent to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic performance of Accexible's digital screening batteryAn average of 1 yearMeasure the odds that a patient has MCI or dementia measured by vocal biomarkers

Secondary

MeasureTime frameDescription
Correlation of Accexible's test battery with the ACE IIIAn average of 1 yearComparison of Accexible's test battery with ACE III diagnostic predictive value at various cut-off points (e.g. 82 and 88 for ACE III)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026